Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06425991 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 20
- Study locations
NCT06425991 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 108 participants, below the 332-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06425991, a Phase 1 study of Relapsed or Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).
Conditions Studied
Interventions
- DRUG Teclistamab
Study Locations (20)
Other
- Flinders Medical Centre - Bedford Park
- Box Hill Hospital - Box Hill
- Royal Prince Alfred Hospital - Camperdown
- Epworth Healthcare - Richmond
- CHRU de Lille Hopital Claude Huriez - Lille
- Hospices Civils de Lyon HCL - Lyon
- CHU Nantes - Nantes
- CHU de Bordeaux - Hospital Haut-Leveque - Pessac
- Klinikum Chemnitz gGmbH - Chemnitz
- Universitaetsklinikum Hamburg Eppendorf - Hamburg
- Universitaetsklinikum Heidelberg - Heidelberg
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Cleveland Clinic Florida - Weston
Georgia
- Augusta University- Georgia Cancer Center - Augusta
Indiana
- St Francis Hospital & Health Centers Indiana Blood and Marrow Transplantation Franciscan Health - Indianapolis
Ohio
- Cleveland Clinic - Cleveland
Texas
- Baylor University Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2024-06-07 |
| Est. Completion | 2027-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06425991
The ClinicalTrials.gov registry entry for NCT06425991 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (67% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Teclistamab is the first listed.
NCT06425991 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT06425991 about?
NCT06425991 is a clinical study titled "A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).
What is the current status of trial NCT06425991?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2024-06-07. Estimated completion is 2027-03-03.
What conditions does trial NCT06425991 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT06425991?
The interventions under investigation include: Teclistamab (DRUG).
Who is sponsoring clinical trial NCT06425991?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06425991 being conducted?
This trial has 20 study locations across Arizona, Colorado, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
-
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
COMPLETED · Phase 1
-
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
COMPLETED · Phase 1
-
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.